Broad-Spectrum Antiviral Therapeutics
Name
Rider-2011-Broad-Spectrum Antiv.pdf
Size
1.25 MB
Format
Adobe PDF
Checksum (MD5)
c719b47d23abf49e93d46a80a1a201a2
Author(s)
Rider, Todd H.
Zook, Christina E.
Boettcher, Tara L.
Wick, Scott T.
Pancoast, Jennifer S.
Zusman, Benjamin D.
Date Issued
July 2011
Journal
PLoS ONE
Publisher
Public Library of Science
Citation
Rider, Todd H. et al. “Broad-Spectrum Antiviral Therapeutics.” Ed. Suryaprakash Sambhara. PLoS ONE 6 (2011): e22572.
Version
Final published version
Abstract
Currently there are relatively few antiviral therapeutics, and most which do exist are highly pathogen-specific or have other disadvantages. We have developed a new broad-spectrum antiviral approach, dubbed Double-stranded RNA (dsRNA) Activated Caspase Oligomerizer (DRACO) that selectively induces apoptosis in cells containing viral dsRNA, rapidly killing infected cells without harming uninfected cells. We have created DRACOs and shown that they are nontoxic in 11 mammalian cell types and effective against 15 different viruses, including dengue flavivirus, Amapari and Tacaribe arenaviruses, Guama bunyavirus, and H1N1 influenza. We have also demonstrated that DRACOs can rescue mice challenged with H1N1 influenza. DRACOs have the potential to be effective therapeutics or prophylactics for numerous clinical and priority viruses, due to the broad-spectrum sensitivity of the dsRNA detection domain, the potent activity of the apoptosis induction domain, and the novel direct linkage between the two which viruses have never encountered.
MIT Department
Lincoln Laboratory
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1371/journal.pone.0022572
